Skip to content
PatentBrief
Get alertsTop ↑

A Chemical Linker for Attaching Drugs to Antibodies

This patent describes specific chemical linkers that can securely attach powerful drug molecules to antibodies, creating targeted therapies like those used in cancer treatment.

Granted 2020ActiveExpires 2038Owned by Rc BiotechnologiesInvented by Lezhi ZHANG, Hui Ye, Jianmin Fang + 1 more

Original patent title: “Covalent linkers in antibody-drug conjugates and methods of making and using the same”

Plain-English explanation by SahiLast reviewed · November 3, 2026

This patent describes specific chemical linkers that can securely attach powerful drug molecules to antibodies, creating targeted therapies like those used in cancer treatment. Granted to Rc Biotechnologies in 2020 with 3 claims and 1 forward citation, and it is expected to expire in 2038.

Coverage

What does this patent actually cover?

This patent provides novel chemical compositions for a "linker-active agent." This agent has two main parts: a "linker" and an "active agent." The linker is specifically designed with a structure (Formula I) that can chemically bond, or "covalently couple," to specific chemical groups called "free thiols" found on an antibody. The "active agent" (Q) is then attached to this linker, and it can be a drug, like a "tubulin binder" or "DNA alkylator," or even a "visualization agent." For example, this technology could be used to attach a chemotherapy drug to an antibody that specifically recognizes cancer cells, allowing the drug to be delivered directly to the tumor.

The gap

What does this patent NOT cover?

  • Linkers that do not attach to "free thiols" on an antibody, such as those that attach to lysine residues.
  • Linkers that do not conform to the specific chemical structure of Formula I as described in claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1.
  • Linkers that use different reactive groups for attachment to the antibody than those listed for R1 and R2 (e.g., maleimide, halogen, alkanal).
  • Linker-active agents that are identical to the specific chemical structure explicitly excluded by the provision in claimclaimA numbered sentence at the end of a patent that legally defines what the inventor owns. The most important section.Read more → 1.
  • Linkers that are not designed to carry an "active agent" such as a drug, enzyme inhibitor, or visualization agent.

These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.

Key facts

Patent numberUS 10772965
StatusActive
FieldBiotech & Medicine
AssigneeRc Biotechnologies
InventorsLezhi ZHANG, Hui Ye, Jianmin Fang and 1 other
Filed2018
Granted2020
Expires2038
Claims3
Times cited1
LitigationNone on record
Value · $72K–$230KModest

What made this novel

The clever bit lies in the precise chemical design of the linker (Formula I) and its reactive groups (R1, R2). This specific architecture allows for stable and controlled covalent attachment to an antibody's thiol groups while also providing a way to carry and potentially release a potent active agent, which is critical for the effectiveness and safety of targeted drug delivery.

The Patent Drawing

Representative patent drawing for Covalent linkers in antibody-drug conjugates and methods of making and using the same (US 10772965)
Representative figure · US 10772965All figures on Google Patents →
Covalent linkers in antibody-d…(Primary claim)pharmaceuticalbiotechoncology

Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.

Where you've seen this

Real-world examples

01

Kadcyla (trastuzumab emtansine)

02

Adcetris (brentuximab vedotin)

03

Enhertu (trastuzumab deruxtecan)

04

Trodelvy (sacituzumab govitecan)

05

Padcev (enfortumab vedotin)

Why it matters

The bigger picture

This patent contributes to the field of Antibody-Drug Conjugates (ADCs), which are a rapidly growing class of targeted cancer therapies. By providing specific, stable linker chemistries, it helps ensure that the drug stays attached to the antibody until it reaches the target cells, minimizing damage to healthy tissues. This precision is crucial for developing safer and more effective treatments for diseases like cancer.

Filed

February 14, 2018

Granted

September 15, 2020

Market context

Who's building on this

Companies in this space

Many major pharmaceutical companies and biotechnology firms are actively developing and commercializing Antibody-Drug Conjugates (ADCs). Companies like Genentech (Roche), AstraZeneca, Seagen (now part of Pfizer), Takeda, and Gilead Sciences are key players in this space, constantly seeking improved linker technologies. Rc Biotechnologies Inc., the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, is also active in this area.

Market impact

This patent's technology contributes to the broader field of Antibody-Drug Conjugates (ADCs), which has created a significant new category of targeted cancer therapies. ADCs offer a promising alternative to traditional chemotherapy by delivering potent drugs directly to cancer cells, potentially reducing systemic side effects. This has spurred substantial investment in oncology drug development and fostered intense competition among pharmaceutical companies to develop novel and more effective ADC platforms.

Claim 1 — Plain English

What this patent covers

This patent provides novel chemical compositions for a "linker-active agent." This agent has two main parts: a "linker" and an "active agent." The linker is specifically designed with a structure (Formula I) that can chemically bond, or "covalently couple," to specific chemical groups called "free thiols" found on an antibody. The "active agent" (Q) is then attached to this linker, and it can be a drug, like a "tubulin binder" or "DNA alkylator," or even a "visualization agent." For example, this technology could be used to attach a chemotherapy drug to an antibody that specifically recognizes cancer cells, allowing the drug to be delivered directly to the tumor.

The clever bit

The clever bit lies in the precise chemical design of the linker (Formula I) and its reactive groups (R1, R2). This specific architecture allows for stable and controlled covalent attachment to an antibody's thiol groups while also providing a way to carry and potentially release a potent active agent, which is critical for the effectiveness and safety of targeted drug delivery.

What it does not cover

  • Linkers that do not attach to "free thiols" on an antibody, such as those that attach to lysine residues.
  • Linkers that do not conform to the specific chemical structure of Formula I as described in claim 1.
  • Linkers that use different reactive groups for attachment to the antibody than those listed for R1 and R2 (e.g., maleimide, halogen, alkanal).
  • Linker-active agents that are identical to the specific chemical structure explicitly excluded by the provision in claim 1.
  • Linkers that are not designed to carry an "active agent" such as a drug, enzyme inhibitor, or visualization agent.

Patent timeline

Filing

Application submitted to the patent office

Publication

Application published, typically 18 months after filing

Grant

Patent officially issued

Expiration

Patent enters public domain

PatentBrief Score

Impact Score

Limited data

Citation count

6/40

Early citations

Claim breadth

2/20

Narrow claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →

Recency

10/20

Granted 5–10 years ago

Assignee scale

0/20

Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →

PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.

Heuristic Value Estimate

What this patent might be worth

Modest

$72K – $230K

Midpoint $144K · 11.2 yr remaining · industry ×3.0

Adjust inputs →

Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.

Claim text not yet imported for this patent

The original legal language

Original claims

3 claims as filed with the patent office.

Concepts involved

ClaimPrior artNon-obviousnessNoveltySpecificationAssigneePatent term

Citations

Patent lineage

Cites earlier patents

15

earlier patents this invention cites as foundations

View prior art →

Cited by later patents

1

later patents that build on this invention

View patents →

Cite this patent

ZHANG, L., Ye, H., Fang, J., & Huang, C. (2020). A Chemical Linker for Attaching Drugs to Antibodies (U.S. Patent No. 10,772,965). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/10772965/covalent-linkers-in-antibody-drug-conjugates-and-methods-of-making-and-using-the

Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.

Embed

Add this patent to your site

Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.

<div data-patentlens-widget data-patent-number="US10772965"></div>
<script src="https://patentbrief.org/embed.js" async></script>

Stay in the loop

Get a weekly digest of new patents.

One email per week. No spam. Unsubscribe anytime.

Keep exploring

Related patents you should know

US 4683195 · 1987

How to Make Billions of Copies of a DNA Segment

This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.

Cetus Corp

US 8697359 · 2014

How to Edit Genes in Human Cells Using an Engineered CRISPR System

This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.

Massachusetts Institute of Technology

US 7657849 · 2010

How the iPhone's Slide-to-Unlock Gesture Works

Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.

Apple Inc

US 4733665 · 1988

How Doctors Implant a Permanent Stent Using a Balloon

This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.

Expandable Grafts Partnership

US 4965188 · 1990

How to Make Many Copies of a DNA Piece with Heat

This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.

Cetus Corp

US 4235871 · 1980

How to Encapsulate Active Materials in Lipid Bubbles Efficiently

This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.

Individual

Semantically similar

You might also find these interesting

SEARCH ALL

More to explore

More in Biotech & Medicine

Browse all Biotech & Medicine

New to patents?

What is a patent?How to read a patentAnatomy of a claimHow strong is this patent?What the citations meanWhat it doesn't coverBiotech PatentsPatent glossary
Explore the landscape:pharmaceutical patents →biotech patents →oncology patents →

Common Questions

Frequently Asked Questions

What does A Chemical Linker for Attaching Drugs to Antibodies cover?

This patent describes specific chemical linkers that can securely attach powerful drug molecules to antibodies, creating targeted therapies like those used in cancer treatment.

Who owns patent US 10772965?

Rc Biotechnologies owns this patent, granted in 2020.

When does this patent expire?

This patent is expected to expire on February 14, 2038, when the invention enters the public domain.

What is patent US 10772965 cited by?

This patent has been cited by 1 later patents that build on its ideas.

What problem does this patent solve?

This patent contributes to the field of Antibody-Drug Conjugates (ADCs), which are a rapidly growing class of targeted cancer therapies. By providing specific, stable linker chemistries, it helps ensure that the drug stays attached to the antibody until it reaches the target cells, minimizing damage to healthy tissues. This precision is crucial for developing safer and more effective treatments for diseases like cancer.

What does this patent NOT cover?

Linkers that do not attach to "free thiols" on an antibody, such as those that attach to lysine residues.

Patent monitoring

Get notified when Rc Biotechnologies files a new patent

Get notified when this company files a new patent. Weekly digest · Confirm via email · Unsubscribe anytime.

Last reviewed: November 3, 2026 · PatentBrief is not a law firm and this is not legal advice.